Intangible Assets, Net

6 Months Ended

Jun. 30, 2026

Intangible Assets, Net [Abstract]

Intangible assets, net

11.

Intangible assets, net

		License # 2 (IPR&D asset)				Customer relationship				Brand				Backlog				Intellectual properties, certifications and other				Total
Cost:
Balance, December 31, 2025		$	2,072,632				682,300				150,000				29,000				-				2,933,932
Additions			15,000				-				-				-				-				15,000
Business combinations			-				1,792,964				131,000				374,054				1,133,141				3,431,159
Balance, June 30, 2026		$	2,087,632				2,475,264				281,000				403,054				1,133,141				6,380,091


Accumulated amortization:
Balance, December 31, 2025		$	-				16,946				14,568				10,021				-				41,535
Amortization			-				55,738				20,312				173,378				95,313				344,741
Balance, June 30, 2026		$	-				72,684				34,880				183,399				95,313				386,276

Net book value:
December 31, 2025		$	2,072,632				665,354				135,432				18,979				-				2,892,397
June 30, 2026			2,087,632				1,966,784				246,120				120,331				1,572,948				5,993,815

License #2:

On March 24, 2026, the Company entered into a third amendment to an existing license agreement related to License #2. The third amendment to the license agreement revised certain development milestone timelines and milestone payment provisions associated with the licensed products in the human health field. Key changes included clarification that, with respect to the licensed product BLS-M22, the Company may initiate a Phase 2 clinical trial without first initiating a Phase 1 clinical trial, subject to providing supporting scientific, preclinical, or regulatory documentation reasonably acceptable to the licensor. The third amendment further clarified that, if Phase 1 clinical trials are bypassed for BLS-M22, the milestone payment associated with initiation of a Phase 1 clinical trial would become payable concurrently with the milestone payment due upon initiation of a Phase 2 clinical trial. In connection with the third amendment, the Company agreed to pay a one-time, non-creditable and non-refundable amendment fee of $15,000.